REG - Shield Therapeutics - Notice of Results and Change in reporting currency

Shield TherapeuticsAnnouncement

06/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230906:nRSF4851La&default-theme=true

RNS Number : 4851L  Shield Therapeutics PLC  06 September 2023

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Notice of interim results

Change in reporting currency

 

London, UK, 6 September 2023: Shield Therapeutics plc (LSE: STX), a
commercial stage pharmaceutical company focused on the commercialisation of
its innovative oral iron therapy for iron deficiency, Accrufer®/Feraccru®
(ferric maltol), will announce its interim results for the six months ended
30 June 2023 on Thursday 28 September 2023.

 

Investor presentation

CEO, Greg Madison, and CFO, Hans-Peter Rudolf, will be hosting a live online
presentation relating to the interim results via the Investor Meet Company
platform at 16.30 (BST) on Thursday 28 September 2023.

 

The presentation is open to all existing and potential investors. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
09:00 (BST) the day before the meeting or at any time during the live
presentation.

Investors can sign up to Investor Meet Company for free and add to
meet Shield Therapeutics plc via:

 

https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
(https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor)

 

Investors who already follow Shield Therapeutics plc on the Investor Meet
Company platform will automatically be invited.

 

Change in reporting currency

Reflecting the increasing importance of the Group's U.S. operations on its
financial results, Shield is also announcing that it will change its reporting
currency from Pounds Sterling to US Dollars (USD) effective 1 January 2023.The
interim results for the six months ending 30 June 2023 will include condensed,
consolidated USD financial information for H123 and FY22. In accordance with
the relevant accounting standards, comparative historic financial information
for FY 2022 will be published in USD alongside the full FY 2023 results in the
first half of 2024.

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Greg Madison, CEO                                                                              +44 (0) 191 511 8500
 Hans-Peter Rudolf, CFO

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel/Patrick Birkholm                                                                   +44 (0)20 7418 8900

 Joint Broker

 finnCap Ltd

 Geoff Nash/ George Dollemore /Nigel Birks/Harriet                                              +44 (0)20 7220 0500
 Ward

 Financial PR & IR Advisor
 Walbrook PR
 Paul McManus/Lianne Applegarth/                                                                +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)

 Alice Woodings

 Investor Contact (US Advisor)

 LifeSci Advisors, LLC

 John Mullaly                                                                                   +1 617 429 3548 or jmullaly@lifesciadvisors.com

 

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral
therapy for adults with iron deficiency, with or without anemia.
Accrufer®/Feraccru® has a novel mechanism of action compared to other oral
iron therapies and has been shown to be an efficacious and well-tolerated
therapy in a range of clinical trials. More information about
Accrufer®/Feraccru®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com)

 

About Shield Therapeutics plc

Shield is a commercial stage pharmaceutical company focused on the
commercialisation of Accrufer®/Feraccru® (ferric maltol), an innovative oral
iron therapy for iron deficiency differentiated from other irons by its
efficacy, broad label and well-tolerated formulation. The Group has launched
Accrufer® in the US with an exclusive, multi-year collaboration agreement
with Viatris, Inc. Feraccru® is commercialised in the UK and European Union
by Norgine B.V., that also have the marketing rights in Australia and New
Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang
Pharmaceutical Co., Ltd., for the development and commercialisation of
Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea
Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc.
in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREAFNSEEADEAA